Geisinger Health System announced that 100,000 participants have enrolled in their MyCode Community Health Initiative, the health system’s biobank and DNA sequencing study.
"MyCode is not only one of the world's largest genomic studies, it's also the most comprehensive with medical record data going back to 1996,” said Geisinger Chief Scientific Officer David H. Ledbetter, PhD. “Combining DNA sequence data with 20 years' worth of medical records is groundbreaking.”
MyCode is a collaboration between Geisinger and Regeneron Pharmaceuticals.
Geisinger said it is returning results to patients who are at risk for 27 conditions, such as Lynch syndrome, which can result in a higher than normal chance of developing colorectal cancer, endometrial cancer, and various other types of aggressive cancers at a young age, or familial hypercholesterolemia.
"When we receive these results, we build this information into our patients' electronic health record which allows us to practice anticipatory medicine," said David T. Feinberg, M.D. MBA, Geisinger president and CEO. "Geisinger is uniquely poised for precision medicine. We're the only organization taking a population health approach to genomics."
Geisinger said that since it reached its initial goal of 100,000 participants so quickly, it is now setting its sights on 250,000 enrolled in the study.